Abstract
The efficacy of low-dose systemic opioids for chronic breathlessness was questioned by the recent Cochrane review by Barnes et al. We examined the reasons for this conflicting finding and re-evaluated the efficacy of systemic opioids. Compared with previous meta-analyses, Barnes et al reported a smaller effect and lower precision, but did not account for matched data of crossover trials (11/12 included trials) and added a risk-of-bias criterion (sample size). When re-analysed to account for crossover data, opioids decreased breathlessness (standardised mean differences −0.32; −0.18 to −0.47; I2=44.8%) representing a clinically meaningful reduction of 0.8 points (0–10 numerical rating scale), consistent across meta-analyses.
| Original language | English |
|---|---|
| Pages (from-to) | 88-90 |
| Number of pages | 3 |
| Journal | Thorax |
| Volume | 73 |
| Issue number | 1 |
| Early online date | 2017 |
| DOIs | |
| Publication status | Published - 1 Jan 2018 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Chronic breathlessness
- Opioids
- Meta-analyses
- Morphine
- COPD Pharmacology
- Perception of Asthma/Breathlessness
- Palliative Care
Fingerprint
Dive into the research topics of 'One evidence base; three stories: do opioids relieve chronic breathlessness?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver